Clinical Trials Logo

Lymphoma, T-Cell clinical trials

View clinical trials related to Lymphoma, T-Cell.

Filter by:

NCT ID: NCT00060385 Terminated - Lymphoma Clinical Trials

Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

Start date: March 2003
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma. PURPOSE: Randomized phase II/III trial to compare the effectiveness of combination chemotherapy with or without etoposide in treating older patients who have non-Hodgkin's lymphoma that has not been previously treated.

NCT ID: NCT00060112 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Start date: March 2003
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of gemcitabine by making cancer cells more sensitive to the drug. This phase I trial is studying the side effects and best dose of oblimersen and gemcitabine in treating patients with metastatic or unresectable solid tumors or lymphoma

NCT ID: NCT00052377 Terminated - Clinical trials for Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Start date: September 2002
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining interleukin-12 with interleukin-2 in treating patients who have mycosis fungoides. Biological therapies, such as interleukin-12 and interleukin-2, use different ways to stimulate the immune system and stop cancer cells from growing. Combining more than one biological therapy may kill more tumor cells

NCT ID: NCT00038883 Terminated - Lymphoma, B-Cell Clinical Trials

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Start date: April 9, 2001
Phase: N/A
Study type: Interventional

High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.

NCT ID: NCT00005982 Terminated - Clinical trials for Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma

Start date: April 2000
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma

NCT ID: NCT00005950 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Start date: April 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00003613 Terminated - Clinical trials for Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Start date: April 1999
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of carmustine given together with O(6)-benzylguanine in treating patients with stage I or stage II cutaneous T-cell lymphoma that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells